TRIDENT™ Platform Technology
The TRIDENT™ platform uses proprietary nanoparticles with pH-responsive coating that selectively activates therapeutics within tumor microenvironments. This intelligent system maintains drug stability during circulation while enabling precise tumor-site release, significantly improving the therapeutic window. The versatile platform accommodates diverse payloads delivering potent cancer treatments precisely where needed.
Introduction to Our Technology
The Science Behind TRIDENT™
TRIDENT™ is a groundbreaking drug delivery platform that integrates EPR-based targeting, endocytosis/cellular uptake, and endosomal escape into a single system (3-in-1). It is specifically designed to carry therapeutic payloads to locate and kill tumors.
Targeted Delivery
Dual Activation Mechanism
Reduced Toxicity
Product Overview
Introducing TRIDENT™ Chemotherapy: A New Era in Chemotherapy Delivery
TRIDENT™ is a revolutionary drug delivery platform designed to address the limitations of current delivery methods. By integrating standard chemotherapy with our TRIDENT™ delivery system, we are able to target the delivery of chemotherapy to the tumor microenvironment and minimize the effect on normal tissues.
TRIDENT™ is not just limited to one application. It’s adaptable to a variety other than therapeutic payloads.
%201.webp)
Delivery Precision.
Target the problem, spare the patient.
Our TRIDENT™ platform is built on a proprietary, multistage-responsive design that enhances therapeutic performance through precise and controlled delivery. A core innovation is its biocompatible, pH-sensitive outer layer, which remains stable during systemic circulation but selectively sheds in the acidic tumor microenvironment. This targeted activation is intended to ensure the nanoparticle remains inert while circulating, significantly reducing systemic toxicity and maximizing on-target bioavailability. Designed to overcome major barriers in nanomedicine delivery, the TRIDENT™ platform offers broad applicability across diverse therapeutic modalities and is strategically positioned for commercial translation.
Versatility.
One platform, endless possibilities.
Xelcis is initially focusing on HER2-negative breast cancer, with plans to expand into additional cancer indications. Its compatibility with multiple chemotherapy agents makes it a versatile solution for a wide range of cancers.
%201.webp)
Speed.
Fast-track innovation, faster results.
We believe we can reduce the development time and cost of bringing TRIDENT™ Chemotherapy to market by leveraging the FDA’s 505(b)(2) regulatory pathway. Backed by a robust patent portfolio and a team of industry experts, the platform is poised for rapid advancement.
Products Benefits
Why Choose TRIDENT™
TRIDENT™ is intended to offer transformative benefits for both patients and healthcare providers
1
Targeted Delivery
Precisely target tumor cells, improving effectiveness and sparing healthy tissues from harmful toxicity.
2
Reduced Toxicity
Minimize severe side effects, including toxicity, by focusing treatment on cancer cells.
3
Enhanced Efficiency
Improve drug distribution, ensuring better therapeutic outcomes with chemotherapy agents.
4
Scalable for Multiple Applications
Initially targeting HER2-negative breast cancer, with potential for other cancers like small-cell lung cancer.
Product Use Cases
Transforming Treatment Across Cancer Types
TRIDENT™ Chemotherapy is not just a solution for one type of cancer—it’s a versatile platform designed to address a wide range of cancer types, starting with HER2-negative breast cancer and expanding into multiple myeloma and small-cell lung cancer and others.
02
Small-Cell Lung Cancer
Lung Cancer
%201.webp)
TRIDENT™ Doxorubicin is also being developed to treat small-cell lung cancer. By delivering TRIDENT™ Doxorubicin directly to SCLC tumors and avoiding normal cells, this approach should minimize damage to healthy tissues and optimize treatment outcomes.
Our goal is to offer:
Directly target small-cell lung cancer cells to reduce tumor growth.
Limit the damage to vital organs, especially the lungs and heart.
Optimize treatment could enhance survival rates in this high-risk cancer type.
01
HER2-Negative Breast Cancer
Solid Tumors
.webp)
TRIDENT™ Doxorubicin is designed to lower toxicity while maintaining efficacy. This design is intended to specifically target cancer cells and avoid normal cells reducing toxicity associated with current chemotherapy agents.
Our goal is to offer:
Targeted release of chemotherapy directly to inside tumor cells.
Lower risk of heart damage compared to current generic doxorubicin treatment.
More effective treatment with fewer systemic complications.